NCT05463419View on ClinicalTrials.gov

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

5,860

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

December 28, 2023

Study Completion Date

April 11, 2024

Conditions
Covid-19 Vaccine
Interventions
BIOLOGICAL

PIKA COVID-19 vaccine

"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."

BIOLOGICAL

Inactivated Covid-19 vaccine

Inactivated SARS-CoV-2 virus

Trial Locations (6)

4104

Health Index Multispecialty Clinic -Clinical Research, Cavite

Unknown

Norzel Medical and Diagnostic Clinical, Cebu

Tropical Disease Foundation, City of Muntinlupa

St. John Hospital, Naga

UERM Research Center, Quezon City

Al Kuwait Hospital, Dubai

All Listed Sponsors
lead

Yisheng Biopharma (Singapore) Pte. Ltd.

INDUSTRY